ImmuPharma plc EBITDA for the year ending December 31, 2023: USD -3.85 M

ImmuPharma plc EBITDA is USD -3.85 M for the year ending December 31, 2023, a 9.40% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • ImmuPharma plc EBITDA for the year ending December 31, 2022 was USD -3.52 M, a -70.13% change year over year.
  • ImmuPharma plc EBITDA for the year ending December 31, 2021 was USD -11.78 M, a 26.01% change year over year.
  • ImmuPharma plc EBITDA for the year ending December 31, 2020 was USD -9.35 M, a 6.04% change year over year.
  • ImmuPharma plc EBITDA for the year ending December 31, 2019 was USD -8.81 M, a -11.49% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)